| Linda M Karadsheh, DO | |
|
15200 Kercheval Ave, Grosse Pointe Park, MI 48230-1356 | |
| (947) 519-6750 | |
| (751) 947-5196 |
| Full Name | Linda M Karadsheh |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 19 Years |
| Location | 15200 Kercheval Ave, Grosse Pointe Park, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942412200 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207VX0000X | Obstetrics & Gynecology - Obstetrics | 5101016508 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beaumont Hospital - Grosse Pointe | Grosse pointe, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| William Beaumont Hospital | 9335051093 | 18 |
News Archive
Anavex Life Sciences Corp. announced today that ANAVEX 2-73 has been named 2010's "most promising trial drug" by the editorial staff at Alzheimer's Weekly. The publication selected the ANAVEX 2-73 trial from a field of over 100 trials that treat dementias such as Alzheimer's and following the review of more than 10,000 articles.
Patients who are divorced, separated or widowed had an approximately 40 percent greater chance of dying or developing a new functional disability in the first two years following cardiac surgery than their married peers, according to a new study from researchers at the Perelman School of Medicine at the University of Pennsylvania published in this week's JAMA Surgery.
Safinamide (trade name: Xadago) has been available since February 2015 as add-on therapy for the treatment of mid- to late-stage Parkinson disease in adults. In combination with levodopa alone or together with other Parkinson disease medicinal products, this monoamine oxidase (MAO-B) inhibitor is used to help restore dopamine levels in the brain.
The study conducted by Prof. Frank Bradke's team provides indications on brain development and about the causes of diseases of the nervous system. The results have now been published in "Neuron".
› Verified 3 days ago
| Entity Name | William Beaumont Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083833875 PECOS PAC ID: 9335051093 Enrollment ID: O20031104000279 |
News Archive
Anavex Life Sciences Corp. announced today that ANAVEX 2-73 has been named 2010's "most promising trial drug" by the editorial staff at Alzheimer's Weekly. The publication selected the ANAVEX 2-73 trial from a field of over 100 trials that treat dementias such as Alzheimer's and following the review of more than 10,000 articles.
Patients who are divorced, separated or widowed had an approximately 40 percent greater chance of dying or developing a new functional disability in the first two years following cardiac surgery than their married peers, according to a new study from researchers at the Perelman School of Medicine at the University of Pennsylvania published in this week's JAMA Surgery.
Safinamide (trade name: Xadago) has been available since February 2015 as add-on therapy for the treatment of mid- to late-stage Parkinson disease in adults. In combination with levodopa alone or together with other Parkinson disease medicinal products, this monoamine oxidase (MAO-B) inhibitor is used to help restore dopamine levels in the brain.
The study conducted by Prof. Frank Bradke's team provides indications on brain development and about the causes of diseases of the nervous system. The results have now been published in "Neuron".
› Verified 3 days ago
| Entity Name | Mclaren Macomb |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396014601 PECOS PAC ID: 8921912791 Enrollment ID: O20040120001000 |
News Archive
Anavex Life Sciences Corp. announced today that ANAVEX 2-73 has been named 2010's "most promising trial drug" by the editorial staff at Alzheimer's Weekly. The publication selected the ANAVEX 2-73 trial from a field of over 100 trials that treat dementias such as Alzheimer's and following the review of more than 10,000 articles.
Patients who are divorced, separated or widowed had an approximately 40 percent greater chance of dying or developing a new functional disability in the first two years following cardiac surgery than their married peers, according to a new study from researchers at the Perelman School of Medicine at the University of Pennsylvania published in this week's JAMA Surgery.
Safinamide (trade name: Xadago) has been available since February 2015 as add-on therapy for the treatment of mid- to late-stage Parkinson disease in adults. In combination with levodopa alone or together with other Parkinson disease medicinal products, this monoamine oxidase (MAO-B) inhibitor is used to help restore dopamine levels in the brain.
The study conducted by Prof. Frank Bradke's team provides indications on brain development and about the causes of diseases of the nervous system. The results have now been published in "Neuron".
› Verified 3 days ago
| Entity Name | Oakwood Ambulatory Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003829441 PECOS PAC ID: 1850282914 Enrollment ID: O20040320000401 |
News Archive
Anavex Life Sciences Corp. announced today that ANAVEX 2-73 has been named 2010's "most promising trial drug" by the editorial staff at Alzheimer's Weekly. The publication selected the ANAVEX 2-73 trial from a field of over 100 trials that treat dementias such as Alzheimer's and following the review of more than 10,000 articles.
Patients who are divorced, separated or widowed had an approximately 40 percent greater chance of dying or developing a new functional disability in the first two years following cardiac surgery than their married peers, according to a new study from researchers at the Perelman School of Medicine at the University of Pennsylvania published in this week's JAMA Surgery.
Safinamide (trade name: Xadago) has been available since February 2015 as add-on therapy for the treatment of mid- to late-stage Parkinson disease in adults. In combination with levodopa alone or together with other Parkinson disease medicinal products, this monoamine oxidase (MAO-B) inhibitor is used to help restore dopamine levels in the brain.
The study conducted by Prof. Frank Bradke's team provides indications on brain development and about the causes of diseases of the nervous system. The results have now been published in "Neuron".
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Linda M Karadsheh, DO 26901 Beaumont Blvd # 3d, Southfield, MI 48033-3849 Ph: (947) 522-1952 | Linda M Karadsheh, DO 15200 Kercheval Ave, Grosse Pointe Park, MI 48230-1356 Ph: (947) 519-6750 |
News Archive
Anavex Life Sciences Corp. announced today that ANAVEX 2-73 has been named 2010's "most promising trial drug" by the editorial staff at Alzheimer's Weekly. The publication selected the ANAVEX 2-73 trial from a field of over 100 trials that treat dementias such as Alzheimer's and following the review of more than 10,000 articles.
Patients who are divorced, separated or widowed had an approximately 40 percent greater chance of dying or developing a new functional disability in the first two years following cardiac surgery than their married peers, according to a new study from researchers at the Perelman School of Medicine at the University of Pennsylvania published in this week's JAMA Surgery.
Safinamide (trade name: Xadago) has been available since February 2015 as add-on therapy for the treatment of mid- to late-stage Parkinson disease in adults. In combination with levodopa alone or together with other Parkinson disease medicinal products, this monoamine oxidase (MAO-B) inhibitor is used to help restore dopamine levels in the brain.
The study conducted by Prof. Frank Bradke's team provides indications on brain development and about the causes of diseases of the nervous system. The results have now been published in "Neuron".
› Verified 3 days ago
Cheryl Gibson Fountain, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 15050 E Jefferson Ave, Grosse Pointe Park, MI 48230 Phone: 313-823-4682 Fax: 313-823-8022 |